|1.||Augood, C: 4 articles (01/2003 - 01/2000)|
|2.||Logan, S: 4 articles (01/2003 - 01/2000)|
|3.||MacLennan, S: 4 articles (01/2003 - 01/2000)|
|4.||Omura, Satoshi: 3 articles (07/2008 - 08/2007)|
|5.||Takanashi, Hisanori: 3 articles (07/2008 - 08/2007)|
|6.||Itoh, Zen: 3 articles (07/2008 - 08/2007)|
|7.||Gilbert, R: 3 articles (01/2003 - 01/2000)|
|8.||Talley, N J: 3 articles (09/2002 - 03/2001)|
|9.||Benatar, A: 3 articles (07/2001 - 12/2000)|
|10.||Vandenplas, Y: 3 articles (07/2001 - 12/2000)|
05/01/1994 - "At the end of cisapride treatment, the most frequently reported symptoms of functional dyspepsia were significantly improved. "
04/01/1995 - "We were unable to show major differences in the short-term efficacy of cisapride and placebo in functional dyspepsia. "
01/01/1993 - "A double-blind, placebo-controlled trial was performed to determine the therapeutic efficacy of cisapride in patients with refractory functional dyspepsia. "
01/01/1989 - "Chronic idiopathic dyspepsia Cisapride has been shown to be effective in both improving symptoms and also delayed gastric emptying in a six week study. "
06/01/1995 - "Cisapride is also effective in improving symptoms in patients with functional dyspepsia. "
|2.||Gastroesophageal Reflux (GERD)
04/01/1993 - "Thus, oral cisapride when taken for 12 weeks promoted healing of oesophagitis and improved symptoms in patients with GERD; although an increase in lower oesophageal sphincter pressure was observed and a reduction in acid reflux was measured, no significant decrease of acid exposure was seen."
06/01/1987 - "A small but significant reduction in the duration of gastro-oesophageal reflux followed cisapride therapy when compared with placebo."
09/01/1997 - "In the acute management of GERD, cisapride is superior to placebo and has the same efficacy as H2 receptor antagonists (H2RAs) in several clinical trials. "
08/01/1998 - "Cisapride, a prokinetic agent, has been reported effective for treating mild-to-moderate grade gastroesophageal reflux disease. "
06/01/1998 - "Cisapride is a prokinetic agent that facilitates gastrointestinal motility and is widely used for the treatment of gastroesophageal reflux disease (GERD) in adults and children. "
07/01/1997 - "Thus long-term cisapride therapy at the study dose produced long-term symptomatic improvement in 42% of patients with severe gastroparesis, with sustained acceleration of gastric emptying for up to 2 years."
05/01/1991 - "We conclude that during a 12-month open trial, cisapride was effective in improving gastric emptying in patients with gastric stasis and consistently improved symptoms in those with gastroparesis."
01/01/1989 - "Diabetic gastroparesis In a four week study, cisapride has been shown to be effective in improving symptoms and solid phase gastric emptying. "
04/10/1995 - "The gastrointestinal prokinetic drug, cisapride, is widely used for the treatment of diabetic gastroparesis and disorders of gastrointestinal motility. "
10/01/1995 - "[Influence on glycemic control of improved diabetic gastroparesis by long-term cisapride therapy]."
01/01/1996 - "To establish whether cisapride is beneficial in children with intractable constipation, an open trial was performed. "
08/01/2002 - "We conclude that cisapride is effective in the treatment of constipation in patients with PSS."
01/01/2000 - "Cisapride was effective in the treatment of children with constipation."
01/01/2000 - "To determine whether cisapride is effective in the treatment of children with constipation. "
01/01/1994 - "We conclude that cisapride is effective in the treatment of constipation in idiopathic PD."
01/01/1996 - "The role of gastric mucosal sulphydryls in the ulcer-protecting effects of cisapride."
08/01/1993 - "This finding was confirmed using lifetable analysis, with a 35% reduction (95% confidence intervals 10-59%, p < 0.05) in the proportion of ulcer relapses in patients who had received cisapride compared with those treated with placebo. "
08/01/1993 - "The 12 month crude relapse rates (that underestimate the probability of ulcer recurrence) showed that cisapride was superior to placebo (34% (11/32) relapsed on cisapride v 68% (23/34) on placebo, p = 0.007). "
01/01/1993 - "Cisapride therapy initiated in functional dyspeptic patients resulted in moderate or marked improvement in 79.1% of the patients with the highest response rates for dysmotility-like (85.2%), reflux-like (81.0%), and non-specific dyspepsia (76.1%) (versus 52.0% for ulcer-like dyspepsia)."
03/01/1987 - "Cisapride caused significant improvement compared with placebo with regard to frequency and severity of symptoms and may therefore be useful in the therapy of non-ulcer dyspepsia."
|8.||Neostigmine (Neostigmine Bromide)
|9.||Glycopyrrolate (Glycopyrronium Bromide)
|1.||Enteral Nutrition (Feeding, Tube)
|2.||Lithotripsy (Extracorporeal Shockwave Lithotripsy)